Arcturus Therapeutics Holdings Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Collaboration Revenue at $16.9 million, 92% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
31
|
18
|
3
|
2
|
7
|
17
|
28
|
29
|
23
|
| Collaboration Revenue |
21
-74.8%
share 70.2%
|
17
+19.1%
share 92.1%
|
1
-96.4%
share 29.7%
|
1
-97.6%
share 29.6%
|
3
-85.3%
share 42.8%
|
14
share 82.5%
|
25
share 86.6%
|
25
share 86.7%
|
21
share 92.2%
|
| Grant |
9
-27.1%
share 29.8%
|
1
-51.8%
share 7.9%
|
2
-45.2%
share 70.3%
|
1
-62.8%
share 70.4%
|
4
+133.0%
share 57.2%
|
3
share 17.5%
|
4
share 13.4%
|
4
share 13.3%
|
2
share 7.8%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 1768224
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.